McDermott and Bull executive Search
 

Other News

Medera Expands Scientific Advisory Board with Leading Heart Failure and Cardiopulmonary Physiology Experts to Advance HFpEF Gene Therapy Program

Financial by 0 comments

Appointments further strengthen clinical leadership as Medera advances its First-In-Human HFpEF gene therapy program toward key upcoming milestonesBOSTON, June 08, 2026 (GLOBE NEWSWIRE) — Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company developing next-generation disease-modifying cardiovascular therapeutics, today announced the appointment of three internationally recognized leaders in heart failure and cardiopulmonary physiology to its Scientific Advisory Board (SAB): Gregory Lewis, MD, Director of Heart Failure & Transplantation at the Massachusetts General Hospital Heart & Vascular Institute and Harvard Medical School; Marat Fudim, MD, MHS, Head of the Heart Failure Unit at Duke University School of Medicine; and Rajeev Malhotra, MD, MS, Associate Director of the Cardiopulmonary Exercise Laboratory at the Massachusetts General Hospital Heart & Vascular Institute and Harvard Medical School. These appointments bring deep expertise in cardiac hemodynamics, exercise physiology, and heart failure pathophysiology—areas central to Medera’s clinical development strategy, particularly in heart failure with preserved ejection fraction (HFpEF), where objective physiological endpoints and functional capacity remain key determinants of therapeutic impact. “We are very pleased to welcome Drs. Lewis, Fudim, and Malhotra to our Scientific Advisory Board,” said Ronald Li, PhD, CEO and Founder of Medera. “As our HFpEF program continues to generate consistent and clinically meaningful signals across cardiac hemodynamics and functional measures, the expanded SAB will provide important guidance in further strengthening the clinical and physiological framework supporting the program’s next stage of development. We look forward to sharing additional clinical updates in the near term.” Scientific Advisory Board Appointments Gregory Lewis, MDDr. Lewis leads the Heart Failure & Transplantation program at Massachusetts General Hospital and directs the Cardiopulmonary Exercise Laboratory. His work has been foundational in defining mechanisms of exercise intolerance in heart failure, including right ventricular–pulmonary vascular interactions and peripheral oxygen utilization—key drivers of symptoms and functional limitation in HFpEF. Dr. Lewis is also Jeffrey & Mary Ellen Jay Endowed Chair in Heart Failure and Professor of Medicine at Harvard Medical School. Marat Fudim, MD, MHSDr. Fudim heads the Heart Failure Unit at Duke University School of Medicine and is a recognized expert in invasive hemodynamics and advanced heart failure management. His clinical and research work focuses on catheter-based assessment and therapeutic strategies to better characterize and treat heart failure physiology. Rajeev Malhotra, MD, MSDr. Malhotra is a leader in cardiopulmonary physiology and cardiovascular translational research at Massachusetts General Hospital and Harvard Medical School. His work integrates human clinical studies with mechanistic insights into vascular biology, metabolism, and cardiac function, supporting the development of novel therapeutic approaches in cardiovascular disease. Medera is advancing a portfolio of AAV-based cardiac gene therapies targeting fundamental drivers of heart failure. Its lead program, SRD-002 for HFpEF, is a single-treatment designed to restore cardiac calcium handling and improve myocardial function. The program utilizes a targeted intracoronary delivery approach designed to enable localized cardiac transduction while minimizing systemic vector exposure. Clinical data generated to date demonstrate consistent and durable improvements in cardiac hemodynamics and functional measures in HFpEF patients, supporting continued advancement toward the next stage of development. Expanded Scientific Advisory Leadership With these appointments, Medera’s SAB represents a highly concentrated group of expertise across heart failure, cardiopulmonary physiology, and translational cardiovascular science. In addition to Drs. Lewis, Fudim, and Malhotra, the SAB includes Brian Jaski, MD (San Diego Cardiac Center); Hesham Sadek, MD, PhD (University of Arizona College of Medicine); Dongsheng Duan, PhD (University of Missouri School of Medicine); Michael Taylor, MD, PhD (Dell Children’s Hospital Medical Center); and Pat Furlong (CEO and Founder of Parent Project Muscular Dystrophy), among others. Collectively, this group has contributed to advancing the understanding of heart failure mechanisms and to shaping the clinical and physiological endpoints used in modern cardiovascular drug development. About Medera Inc. Medera is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for cardiovascular and other serious diseases. Its pipeline includes multiple AAV-based gene therapy programs targeting heart failure and related conditions. Medera operates through two core business units: Novoheart, which provides human-specific cardiac disease modeling and drug discovery platforms, and Sardocor, which leads clinical development of the company’s gene therapy pipeline. Together, these capabilities enable a translational approach bridging human-relevant discovery with clinical development. For more information, please visit www.medera.bio. Contacts Ally StubinPublic RelationsICR HealthcareAlly.stubin@icrhealthcare.com646.667.1861 Stephanie CarringtonInvestor RelationsICR HealthcareStephanie.carrington@icrhealthcare.com646.277.1282

Continue Reading →

BioCardia Announces $4.4 Million Financing

Financial by 0 comments

Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash runway would extend well beyond PMDA approval and into first commercial sales. SUNNYVALE, Calif., June 08, 2026 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, sold 3,509,604 shares at an average price of $1.279 on Friday, June 5, 2026. No warrants were issued in this capital raise. About BioCardia® BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information visit www.biocardia.com. Upcoming Catalysts in 2026: CardiAMP HF Manuscript PublishedCardiAMP HF Japan PMDA Submission Q4 2026 Forward Looking Statements: This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements relating to submission for and subsequent market clearance of the CardiAMP Cell Therapy. These forward-looking statements are made as of the date of this press release. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Media Contact: Miranda Peto, Investor RelationsEmail: mpeto@BioCardia.comPhone: 650-226-0120 Investor Contact: David McClung, Chief Financial OfficerEmail: investors@BioCardia.comPhone: 650-226-0120

Continue Reading →

InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures

Peripheral/Endo Regulatory by 0 comments

MIAMI, June 08, 2026 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (“NPS”), for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization (“TCAR”) procedures. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio.

Continue Reading →

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

Coronary/Structural Heart Regulatory by 0 comments

MINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This authorization marks a significant milestone in the Company’s clinical and regulatory strategy and enables patient recruitment to commence at leading centers in France. “Securing French regulatory clearance is an important step in the execution of the PARADIGM Trial,” said Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris. “France represents a strategically important market with highly experienced centers and investigators, reinforcing the quality and conduct of the study.” The Company continues to advance its global clinical strategy, with ongoing site activations and patient enrollment across the United States and Europe. About the PARADIGM Trial The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR® Transcatheter Heart Valve compared to commercially available transcatheter aortic valve replacements (TAVRs). This head-to-head study will enroll approximately 1,000 patients in the ‘All Comers Randomized Cohort’ with 1:1 randomization of patients who will receive either the DurAVR® THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure. For further information, please refer to ClinicalTrials.gov NCT07194265. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris’ lead product, the DurAVR® THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. Forward-Looking Statements This announcement contains forward-looking statements, including statements regarding the expectation that patient recruitment will commence in France. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Actual future events may vary from these forward-looking statements and readers are cautioned not to put undue reliance on forward-looking statements. Other than as required by law, Anteris gives no representation or guarantee that the occurrence of any of the events or circumstances expressed or implied in these statements will occur. In addition, except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations. For more information:  Global Investor RelationsInvestor Relations (US)investors@anteristech.commchatterjee@bplifescience.comDebbie OrmsbyMalini Chatterjee, Ph.D.Anteris Technologies Global Corp.Blueprint Life Science Group+61 1300 550 310 | +61 7 3152 3200+1 917 330 4269 Websitewww.anteristech.comX@AnterisTechLinkedInhttps://www.linkedin.com/company/anteristech

Continue Reading →

FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF

Coronary/Structural Heart by 0 comments

SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its Q-Sub Meeting with FDA Center for Biologics Evaluation and Research (CBER) on the CardiAMP Cell Therapy System for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF). The meeting minutes from FDA confirm that the ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) for market clearance. PMA is the most rigorous type of device marketing application required by the agency. It is used to establish the safety and effectiveness of high-risk medical devices prior to them being approved for public use. FDA had previously indicated that they typically like to see two well designed trials for approval, particularly in large clinical indications such as HFrEF, where there are potentially over one million patients who could benefit from CardiAMP Cell Therapy in the United States. FDA has also previously demonstrated that they consider the CardiAMP Cell Therapy System safe, as this FDA determination is required to enable the Centers for Medicare and Medicaid to reimburse in the CardiAMP HF trials. “Patients with ischemic Heart Failure of reduced Ejection Fraction are in great need for therapeutic options,” said Peter Altman, PhD, BioCardia’s Chief Executive Officer. “FDA recognizes this need and the strengths in our completed CardiAMP HF clinical data to be the first of two trials to support Premarket Approval.” About CardiAMP Cell Therapy Granted FDA Breakthrough designation, CardiAMP Cell Therapy uses a patient’s own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure intended to increase capillary density and reduce tissue fibrosis of myocardial tissue to address microvascular dysfunction. Japan Pharmaceutical and Medical Device Agency has indicated that the clinical results from three completed clinical trials for the treatment of ischemic heart failure likely provide sufficient evidence of safety and efficacy to support a successful submission for approval. Clinical development of the CardiAMP Cell Therapy for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Centers for Medicare and Medicaid Services (CMS). CAUTION – Limited by United States law to investigational use.  About BioCardia® BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information visit www.biocardia.com. Upcoming Catalysts in 2026: CardiAMP HF Manuscript PublishedCardiAMP HF Japan PMDA Submission Q4 2026 Forward Looking Statements: This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements relating to submission for and subsequent market clearance of the CardiAMP Cell Therapy. These forward-looking statements are made as of the date of this press release. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Media Contact: Miranda Peto, Investor RelationsEmail: mpeto@BioCardia.comPhone: 650-226-0120 Investor Contact: David McClung, Chief Financial OfficerEmail: investors@BioCardia.comPhone: 650-226-0120

Continue Reading →

JenaValve Appoints Maria Jose Arana as Vice President of Quality and Compliance

Financial by 0 comments

IRVINE, Calif., June 03, 2026 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy® Transcatheter Heart Valve (THV) System, today announced the appointment of Maria Jose Arana as Vice President of Quality and Compliance. Maria Jose will lead the company’s quality assurance and compliance strategy, overseeing the implementation of critical quality and compliance systems as JenaValve expands its commercial operations and advances its clinical programs. Her appointment continues the company’s commitment to quality and patient safety during a pivotal period of organizational growth and commercial expansion following the recent FDA approval of the Trilogy THV System for high risk, symptomatic, severe aortic regurgitation (ssAR). Maria Jose brings more than 25 years of executive leadership experience in quality and regulatory affairs across medical devices, diagnostics, and combination product environments. She has a proven track record of building and scaling compliant Quality Management Systems (QMS), advancing regulatory workflows, and leading global inspection readiness programs across organizations. Most recently, Maria Jose served as Senior Director of Quality & Compliance at Johnson & Johnson Electrophysiology, where she led global Quality Systems, Compliance, and Quality Engineering organizations of more than 300 employees across cardiovascular device portfolios spanning predevelopment through commercialization. Prior to J&J, she served as Head of Quality & Compliance at Accriva Diagnostics, leading global QMS and validation teams across multiple markets. She also held quality and regulatory leadership roles at Volcano Corporation, CryoCor, and Medtronic Vascular. Maria Jose holds advanced degrees from Instituto Tecnologico de Monterrey and is certified as a Six Sigma Black Belt and ISO 13485 Lead Auditor. “Maria Jose’s appointment comes at an important moment for JenaValve,” said John Kilcoyne, CEO of JenaValve. “With FDA approval and U.S. commercial launch behind us, we are expanding meaningfully, and the quality and compliance infrastructure we build now will be foundational to our long-term success. Maria Jose brings quality and compliance expertise, cross-functional partnership skills, and the depth of leadership that this stage of growth demands. I look forward to working closely with her as we continue to advance the Trilogy System and expand access to treatment for patients suffering from high risk ssAR.” “I am thrilled to join JenaValve at such a defining moment in the company’s evolution,” said Maria Jose Arana, Vice President of Quality and Compliance at JenaValve. “The clinical evidence supporting the Trilogy System is compelling, and the opportunity to build a world-class quality organization that supports both the commercial launch in the U.S. and the ongoing ARTIST trial is an incredible privilege. I look forward to partnering with the JenaValve team to ensure the highest standards of quality and compliance as we work to bring this life-changing therapy to the broadest group of patients suffering from AR.” About the Trilogy™ THV SystemThe Trilogy THV System is the first and only transcatheter heart valve in the United States indicated for native, symptomatic, severe aortic regurgitation in patients who are judged by a Heart Team to be at high or greater risk for surgical aortic valve replacement. The Trilogy THV System received CE Mark in 2021, and has now been used in more than 1,000 commercial procedures in Europe. The Trilogy System was purpose-built to address the unique anatomical challenges of aortic regurgitation (AR). Unlike conventional TAVR valves that rely on annular calcification for anchoring — which is typically absent in AR patients — the Trilogy System features three proprietary radiopaque locators that attach directly to the native aortic leaflets, enabling secure and stable implantation even in the absence of calcium. The locators also provide commissural alignment for precise valve positioning and ensure a reliable seal to minimize paravalvular regurgitation. The system’s large, open-cell nitinol frame is designed to preserve future coronary access. About JenaValveJenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative THV solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy THV System is a TAVR system designed to treat patients with symptomatic, severe AR, and symptomatic, severe aortic stenosis (AS) who are at high surgical risk. The Trilogy THV System has regulatory approvals in the United States and Europe for its intended use, and reflects JenaValve’s focus on addressing unmet clinical needs in aortic valve disease, including aortic regurgitation. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, United Kingdom, and Munich, Germany. JenaValve is backed by Bain Capital Life Sciences, Andera Partners, Valiance Life Sciences, Rosetta Capital, Cormorant Asset Management, Legend Capital, NeoMed Management, RMM, VI Partners, Pictet Alternative Advisors SA, Qatar Investment Authority (QIA), Innovatus Capital Partners, and Peijia Medical Limited. Additional information is available at www.jenavalve.com. JenaValve Contact:Daniel Sun dsun@jenavalve.com Investor Contacts:Marissa Bych or Webb CampbellGilmartin Group LLCWebb@Gilmartinir.com

Continue Reading →

RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities

Financial by 0 comments

LOS ANGELES, June 03, 2026 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of outpatient imaging centers and a premier developer of radiology digital health solutions, today announced that it seeks to secure an incremental term loan in the aggregate principal amount of $200 million (the “Proposed 2026 Incremental Term Loan”) pursuant to a proposed amendment (the “Proposed Amendment”) to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the “Existing Credit Agreement” and, the transaction, the “Loan Transaction”).

Continue Reading →

Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens

Financial Rhythm by 0 comments

Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic’s commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of technologies GALWAY, Ireland, June 3, 2026 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global…

Continue Reading →
1 2 3 … 1,342